Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

The structural basis for the function of two anti-VEGF receptor 2 antibodies.

Franklin MC, Navarro EC, Wang Y, Patel S, Singh P, Zhang Y, Persaud K, Bari A, Griffith H, Shen L, Balderes P, Kussie P.

Structure. 2011 Aug 10;19(8):1097-107. doi: 10.1016/j.str.2011.01.019.

2.

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.

Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM.

Structure. 1998 Sep 15;6(9):1153-67.

PMID:
9753694
3.

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.

Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z.

J Biol Chem. 2003 Oct 31;278(44):43496-507. Epub 2003 Aug 12.

4.

Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3.

Rinderknecht M, Villa A, Ballmer-Hofer K, Neri D, Detmar M.

PLoS One. 2010 Aug 2;5(8):e11941. doi: 10.1371/journal.pone.0011941.

5.
6.

Structural determinants of growth factor binding and specificity by VEGF receptor 2.

Leppänen VM, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, Lankinen H, Goldman A, Ballmer-Hofer K, Alitalo K.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2425-30. doi: 10.1073/pnas.0914318107.

7.

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.

Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB.

J Mol Biol. 1999 Nov 5;293(4):865-81.

PMID:
10543973
8.

The antiangiogenic activity of a soluble fragment of the VEGFR extracellular domain.

Li H, Cao W, Chen Z, Acheampong DO, Jin H, Li D, Zhang J, Wang M.

Biomed Pharmacother. 2013 Sep;67(7):599-606. doi: 10.1016/j.biopha.2013.06.001. Epub 2013 Jul 10.

PMID:
23906761
9.

Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.

Ghavamipour F, Shahangian SS, Sajedi RH, Arab SS, Mansouri K, Aghamaali MR.

FEBS J. 2014 Oct;281(19):4479-94. doi: 10.1111/febs.12956. Epub 2014 Sep 1.

10.

Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody.

Karpusas M, Lucci J, Ferrant J, Benjamin C, Taylor FR, Strauch K, Garber E, Hsu YM.

Structure. 2001 Apr 4;9(4):321-9.

11.

A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3.

Jimenez X, Lu D, Brennan L, Persaud K, Liu M, Miao H, Witte L, Zhu Z.

Mol Cancer Ther. 2005 Mar;4(3):427-34.

12.

Crystal structure of human vascular endothelial growth factor-B: identification of amino acids important for receptor binding.

Iyer S, Scotney PD, Nash AD, Ravi Acharya K.

J Mol Biol. 2006 May 26;359(1):76-85. Epub 2006 Apr 17.

PMID:
16616187
13.

Crystal structure of vascular endothelial growth factor-B in complex with a neutralising antibody Fab fragment.

Leonard P, Scotney PD, Jabeen T, Iyer S, Fabri LJ, Nash AD, Acharya KR.

J Mol Biol. 2008 Dec 31;384(5):1203-17. doi: 10.1016/j.jmb.2008.09.076. Epub 2008 Oct 9.

PMID:
18930733
14.

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

Miao HQ, Hu K, Jimenez X, Navarro E, Zhang H, Lu D, Ludwig DL, Balderes P, Zhu Z.

Biochem Biophys Res Commun. 2006 Jun 23;345(1):438-45. Epub 2006 May 2.

PMID:
16682007
15.

Structure of IL-17A in complex with a potent, fully human neutralizing antibody.

Gerhardt S, Abbott WM, Hargreaves D, Pauptit RA, Davies RA, Needham MR, Langham C, Barker W, Aziz A, Snow MJ, Dawson S, Welsh F, Wilkinson T, Vaugan T, Beste G, Bishop S, Popovic B, Rees G, Sleeman M, Tuske SJ, Coales SJ, Hamuro Y, Russell C.

J Mol Biol. 2009 Dec 18;394(5):905-21. doi: 10.1016/j.jmb.2009.10.008. Epub 2009 Oct 14.

PMID:
19835883
16.

Identification of ligand-binding site III on the immunoglobulin-like domain of the granulocyte colony-stimulating factor receptor.

Layton JE, Hall NE, Connell F, Venhorst J, Treutlein HR.

J Biol Chem. 2001 Sep 28;276(39):36779-87. Epub 2001 Jul 23.

17.

Mutual conformational adaptations in antigen and antibody upon complex formation between an Fab and HIV-1 capsid protein p24.

Monaco-Malbet S, Berthet-Colominas C, Novelli A, Battaï N, Piga N, Cheynet V, Mallet F, Cusack S.

Structure. 2000 Oct 15;8(10):1069-77.

18.

Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.

Ran S, Huang X, Downes A, Thorpe PE.

Neoplasia. 2003 Jul-Aug;5(4):297-307. doi: 10.1016/S1476-5586(03)80023-4.

19.

Periplasmic expression optimization of VEGFR2 D3 adopting response surface methodology: antiangiogenic activity study.

Cao W, Li H, Zhang J, Li D, Acheampong DO, Chen Z, Wang M.

Protein Expr Purif. 2013 Aug;90(2):55-66. doi: 10.1016/j.pep.2013.04.010. Epub 2013 May 13.

PMID:
23680780
20.

Supplemental Content

Support Center